Subtopic Deep Dive
Anti-TNF Therapy in Uveitis
Research Guide
What is Anti-TNF Therapy in Uveitis?
Anti-TNF therapy in uveitis uses tumor necrosis factor inhibitors like infliximab and adalimumab to treat refractory ocular inflammation in Behçet's disease and noninfectious uveitis.
Studies show infliximab rapidly controls sight-threatening inflammation in Behçet's uveitis (Sfikakis et al., 2004, 228 citations). Multicenter trials compare infliximab and adalimumab efficacy in refractory uveitis, with adalimumab offering subcutaneous administration (Vallet et al., 2016, 170 citations). Expert reviews recommend anti-TNF agents for steroid-dependent or vision-threatening cases (Touhami et al., 2019, 66 citations). Over 20 papers from 2004-2020 analyze long-term outcomes and safety.
Why It Matters
Anti-TNF therapies preserve vision in Behçet's uveitis patients unresponsive to steroids and immunosuppressants, as shown in Sfikakis et al. (2004) where infliximab halted recurrent inflammation in all cases. Vallet et al. (2016) multicenter study found similar efficacy between infliximab and adalimumab, guiding treatment choice based on administration route and safety profiles. Touhami et al. (2019) expert opinion supports biologics for severe uveitis, reducing relapse rates and corticosteroid dependence in clinical practice. Mesquida et al. (2013) highlight pathways to remission, impacting ophthalmology guidelines.
Key Research Challenges
Long-term Safety Profiles
Anti-TNF agents risk infections and malignancies in prolonged uveitis treatment (Touhami et al., 2019). Vallet et al. (2016) report adverse events in multicenter data, requiring monitoring strategies. Balancing efficacy against risks remains unresolved in Behçet's cohorts.
Optimal Agent Selection
Infliximab and adalimumab show comparable efficacy, but factors like route and dosing vary (Vallet et al., 2016). Schwartzman (2016) discusses biologic choices in uveitis management. Personalized selection lacks randomized head-to-head trials.
Biomarker Response Prediction
TNF levels correlate with response, but predictors for remission are unclear (Mesquida et al., 2013). Sfikakis et al. (2004) note rapid control without biomarkers. Identifying responders before therapy initiation needs validation.
Essential Papers
Infliximab for Recurrent, Sight-Threatening Ocular Inflammation in Adamantiades–Behçet Disease
Petros P. Sfikakis, P Kaklamanis, Antonia Elezoglou et al. · 2004 · Annals of Internal Medicine · 228 citations
Letters2 March 2004Infliximab for Recurrent, Sight-Threatening Ocular Inflammation in Adamantiades–Behçet DiseaseP. P. Sfikakis, MD, P. H. Kaklamanis, MD, A. Elezoglou, MD, N. Katsilambros, MD, P. ...
Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network
Hélène Vallet, P. Sève, Lucie Biard et al. · 2016 · Arthritis & Rheumatology · 170 citations
Objective To analyze the factors associated with response to anti–tumor necrosis factor (anti‐TNF) treatment and compare the efficacy and safety of infliximab (IFX) and adalimumab (ADA) in patients...
Expert opinion on the use of biological therapy in non-infectious uveitis
Sara Touhami, É. Diwo, P. Sève et al. · 2019 · Expert Opinion on Biological Therapy · 66 citations
In case of dependency to steroids or sight-threatening disease, conventional immunosuppressive drugs (methotrexate, azathioprine and mycophenolate mofetil) and/or biological therapies such as anti-...
Current and future treatments for Behçet’s uveitis: road to remission
Marina Mesquida, Blanca Molins, Víctor Llorenç et al. · 2013 · International Ophthalmology · 46 citations
Advancements in the management of uveitis
Sergio Schwartzman · 2016 · Best Practice & Research Clinical Rheumatology · 42 citations
The Use of Biologic Therapies in Uveitis
Sergio Schwartzman, Monica Schwartzman · 2014 · Clinical Reviews in Allergy & Immunology · 30 citations
One year in review 2019: Behçet's syndrome.
Gülen Hatemi, Emire Seyahi, İzzet Fresko et al. · 2020 · PubMed · 25 citations
Several epidemiologic studies report on the prevalence of Behçet's syndrome (BS) and demographic and clinical findings in patients from different countries and ethnicities. Although these studies p...
Reading Guide
Foundational Papers
Read Sfikakis et al. (2004, 228 citations) first for infliximab's rapid control in sight-threatening Behçet's uveitis; then Mesquida et al. (2013, 46 citations) for remission pathways; Schwartzman (2014, 30 citations) for biologic overview.
Recent Advances
Study Vallet et al. (2016, 170 citations) for infliximab vs adalimumab comparison; Touhami et al. (2019, 66 citations) for biologic guidelines; Hatemi et al. (2020, 25 citations) for Behçet's updates.
Core Methods
Core methods: Multicenter cohorts tracking relapse-free survival (Vallet 2016); rapid infusion protocols (Sfikakis 2004); GRADE-assessed expert recommendations (Touhami 2019); survival analysis for remission (Mesquida 2013).
How PapersFlow Helps You Research Anti-TNF Therapy in Uveitis
Discover & Search
Research Agent uses searchPapers('Anti-TNF uveitis Behçet') to retrieve Sfikakis et al. (2004, 228 citations), then citationGraph reveals forward citations like Vallet et al. (2016). findSimilarPapers on Sfikakis expands to Touhami et al. (2019); exaSearch uncovers French Uveitis Network data.
Analyze & Verify
Analysis Agent applies readPaperContent to extract efficacy metrics from Vallet et al. (2016), verifies response rates with verifyResponse (CoVe) against GRADE grading for moderate evidence in refractory uveitis. runPythonAnalysis plots survival curves from multicenter data using pandas for statistical verification.
Synthesize & Write
Synthesis Agent detects gaps in long-term pediatric data via gap detection on Poddighe et al. (2019), flags contradictions between infliximab rapidity (Sfikakis et al., 2004) and adalimumab convenience (Vallet et al., 2016). Writing Agent uses latexEditText, latexSyncCitations for Sfikakis/Vallet, latexCompile for review manuscripts, exportMermaid for treatment outcome flowcharts.
Use Cases
"Compare relapse rates in infliximab vs adalimumab for Behçet's uveitis using meta-analysis"
Research Agent → searchPapers + citationGraph → Analysis Agent → readPaperContent (Vallet 2016) → runPythonAnalysis (pandas meta-analysis forest plot) → GRADE B evidence output with CSV export.
"Draft LaTeX review on anti-TNF safety in uveitis citing Sfikakis and Touhami"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (Sfikakis 2004, Touhami 2019) → latexCompile → PDF with synchronized bibliography.
"Find code for uveitis response modeling from anti-TNF papers"
Research Agent → searchPapers('anti-TNF uveitis simulation') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis (NumPy survival models) → verified code output.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (50+ anti-TNF uveitis papers) → citationGraph → DeepScan (7-step verifyResponse/CoVe on Sfikakis/Vallet) → structured report with GRADE scores. Theorizer generates hypotheses on remission biomarkers from Mesquida et al. (2013) + recent Hatemi (2020), chaining gap detection to exportMermaid diagrams. DeepScan analyzes Vallet (2016) multicenter data with runPythonAnalysis checkpoints.
Frequently Asked Questions
What defines anti-TNF therapy in uveitis?
Anti-TNF therapy targets TNF-alpha with agents like infliximab (IV) and adalimumab (SC) for refractory noninfectious uveitis and Behçet's ocular inflammation.
What are key methods in anti-TNF uveitis studies?
Methods include multicenter retrospective cohorts (Vallet et al., 2016), case series for rapid response (Sfikakis et al., 2004), and expert consensus on steroid-sparing (Touhami et al., 2019).
What are the most cited papers?
Sfikakis et al. (2004, 228 citations) shows infliximab efficacy in Behçet's uveitis; Vallet et al. (2016, 170 citations) compares infliximab/adalimumab; Touhami et al. (2019, 66 citations) provides biologic recommendations.
What open problems exist?
Challenges include long-term safety, biomarker predictors for response, and head-to-head RCTs for agent selection in pediatric Behçet's uveitis (Poddighe et al., 2019).
Research Ocular Diseases and Behçet’s Syndrome with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Anti-TNF Therapy in Uveitis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers